Bioventus Inc. - Class A Common Stock (BVS)

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Bioventus (BVS) reported strong Q3 2025 earnings, beating EPS estimates with a 200% surge. While revenue slightly missed, organic growth was up 8.2%.

Bioventus Inc. (BVS) reports mixed Q2 2025 results with slight revenue miss but EPS near estimates. Organic growth up 6.2%, yet stock dips 2% pre-market.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

Bioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Solventum stock saw a positive improvement to its Relative Strength Rating on Tuesday, with an upgrade from 78 to 81.

BVS stock results show that Bioventus beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Learn more about the growth stocks under $10 with progressive fundamentals in the healthcare and technology sectors.

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!